CoChat
Sign Up
Cited by 256Pain Management and Placebo EffectTreatment of Major DepressionStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Placebo Response in Randomized Controlled Trials of Antidepressants for Pediatric Major Depressive Disorder

Bridge, Jeffrey A., Birmaher, Boris, Iyengar, Satish, Barbe, Rémy P., Brent, David A.·2009·American Journal of Psychiatry
DOI 10.1176/appi.ajp.2008.08020247
Open this paper in CoChat — free account

Abstract

Objective: The authors examined characteristics and predictors of response to placebo in all available reports of short-term randomized controlled trials of antidepressants for pediatric major depressive disorder. Method: Response, defined as a score ≤2 on the improvement item of the Clinical Global Impression scale, and potential predictors were extracted from 12 published and unpublished randomized controlled trials of second-generation antidepressants in participants 6–18 years of age with major depression. Results: The single best predictor of the proportion of patients taking placebo who responded to treatment was the number of study sites. Baseline severity of illness also emerged as a significant inverse predictor of placebo response, although the strength of this relationship was diminished when number of sites was controlled for. After one large fluoxetine trial was excluded, younger participants showed a higher placebo response rate than older adolescents. Higher placebo response rates in more recent studies were explained by an increasing trend toward large multisite trials and by publication delays and failures to publish some negative trials. Conclusions: The recent shift toward large multisite trials of antidepressant medications for pediatric major depression may be contributing to an increasing incidence of response to placebo. Pharmacotherapy studies of pediatric depression that carefully recruit patients with at least moderately severe depression may be more informative and efficient than many trials conducted to date. Such studies should have sufficient power to determine whether age moderates medication and placebo response.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2008.08020247

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 48 references

Research works printed but not linked: 11

  1. Koppelman J, 2004, NHPF Issue Brief, 801, 1
  2. Wilcox CS, 1992, Psychopharmacol Bull, 28, 157
  3. Hammad TA, 2004, Review and evaluation of clinical data
  4. Poznanski E, 1995, Mokros H: Children's Depression Rating Scale-Revised (CDRS-R)
  5. March J, JAMA 2004; 292: 807-820
  6. Emslie GJ, 2002, J Child Adolesc Psychopharmacol, 12, 299
  7. Dubitsky GM, 2004, Review and evaluation of clinical data: placebocontrolled antidepressant studies in pediatric patients
  8. US Food and Drug Administration, 2002, NDA: 20-152. S-032, nefazodone hydrochloride (Serzone).
  9. Emslie GJ, 2002, 42nd Annual Meeting of the National Institute of Mental Health: New Clinical Drug Evaluation Unit (NCDEU). Boca Raton
  10. Birmaher B, 2000, Comorbid ADHD and other disruptive behavior disorders as predictors of response in adolescents treated for major depression, poster, 153rd annual meeting of the American Psychiatric Association
  11. Breiman L, 1984, Olshen RA

Cited by

Sorted by citations

Items 201–254 of 254

Related

See all

Metadata

Authors
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A.
Affiliations
Nationwide Children's Hospital (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2009-01
Volume
166
Issue
1
Pages
42-49
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.2008.08020247
OpenAlex
W2137044513
Cited by
256
References
48
Citations by year
2026: 6 · 2025: 9 · 2024: 11 · 2023: 2 · 2022: 12 · 2021: 12 · 2020: 9 · 2019: 14 · 2018: 19 · 2017: 16 · 2016: 14 · 2015: 27 · 2014: 22 · 2013: 14 · 2012: 12
FWCI
1.40
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (K01 MH-69948, K01MH069948, P30MH066371, P30 MH-66371)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
placebo response, antidepressants, second-generation antidepressants, age differences, publication bias, Clinical Global Impression Scale, multisite trials, fluoxetine
MeSH terms
Adolescent, Age Factors, Child, Major Depressive Disorder, Humans, Personality Assessment, Multicenter Studies as Topic, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome, Publication Bias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review